Medivir AB engages in the development of pharmaceuticals products. The firm focuses on the discovery and development of transformative active cancer drugs. Its portfolio includes proprietary pipelines such as remetinostat, birinapant, MV-818, MV-828, and MIV-711 projects; and partnership pipeline which covers xerclear and MIV-802 project. The company was founded in 1988 and is headquartered in Huddinge, Sweden.

Sankyo Co., Ltd. engages in the manufacture and sale of pachinko and pachislot machines. It operates through the following segments: Pachinko Machines Business, Pachislot Machines Business, Ball Bearing Supply Systems Business, and Others. The Pachinko Machines Business segment produces and sells pachinko machines, machine gauges and its related parts. The Pachislot Machines Business segment markets pachislot machines and related parts. The Ball Bearing Supply Systems segment sells pachinko and pachislot ball feeders, card system equipment, and parlor-related equipment. The Others segment comprises of mobile content service, real estate, golf club operations, and sells general molding products. The company was established on April 12, 1966 and is headquartered in Tokyo, Japan.

Abbisko Therapeutics Co., Ltd. engages in the research and development of biomedicine and biotechnology. Its business includes technology transfer, technical advisory, and technical services. The company was founded on April 12, 2016 and is headquartered in Shanghai, China.

Exelixis is focused on discovering, developing and commercializing therapies for the treatment of cancer and other serious diseases. The majority of its programs focus on the discovery and development of small molecule drugs for cancer. The Company has a pipeline of compounds in various stages of development for the treatment of cancer and various metabolic, cardiovascular and inflammatory disorders. All of its development compounds were generated through its internal drug discovery activities, although it is developing certain of these compounds in collaboration with partners and has out-licensed to others. The Company is focusing its development activities on its clinical compounds, XL184, XL147 and XL765. XL184, the Company's advanced drug candidate, inhibits MET, VEGFR2 and RET, proteins that are key drivers of tumor growth and/or vascularization. XL147 is a selective inhibitor of PI3K while XL765 is a dual inhibitor of PI3K and mTOR.

Yafei (Shanghai) Biomedical Technology Co., Ltd. is a Chinese company located in Shanghai that engages in research and development of biomedical technologies & products.

Plexxikon, Inc. engages in the discovery and development of small molecule pharmaceuticals to treat human disease. The company's products include PLX204 for the treatment of diabetes; PLX4032 for the treatment of melanoma and colorectal cancer; and PLX5568 kinase inhibitors for the treatment of pain, polycystic kidney disease, rheumatoid arthritis, metastatic breast cancer, and renal disease. It develops a portfolio of clinical and preclinical stage programs in various therapeutic areas, including metabolic disease, such as obesity indications; oncology, such as osteolytic metastatic disease; and CNS, such as multiple sclerosis. The company’s portfolio of clinical and preclinical stage programs for other therapeutic areas include inflammation, such as systemic lupus erythematosus, inflammatory bowel disease, and osteoporosis; and cardiovascular, including hypertension and atherosclerosis.

Janssen Pharmaceutica is a pharmaceutical company headquartered in Beerse, Belgium and owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen. In 1961, Janssen Pharmaceutica was purchased by New Jersey-based American corporation Johnson & Johnson, and became part of Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), now renamed to Janssen Research and Development (JRD), which conducts research and development activities related to a wide range of human medical disorders, including mental illness, neurological disorders, anaesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies and cancer. Janssen and Ortho-McNeil Pharmaceutical have been placed in the Ortho-McNeil-Janssen group within Johnson & Johnson Company.

Heidelberg Pharma AG is a biopharmaceutical company, which engages in the research and development of drugs for cancer patients. The firm focuses on oncology; and development Amanitin, a toxin used in cancer therapies. It also offers tumor implantation models, inflammatory and autoimmune diseases, and bioanalytics services. The company was founded by Olaf G. Wilhelm, Manfred Schmitt, Viktor Magdolen, Heinrich Graeff, Bernd Gänsbacher, Horst Kessler, Peter Nawroth, and Thomas Luther in September 1997 and is headquartered in Ladenburg, Germany.

Qingdao Chenda Biotechnology Co., Ltd., established on 2015-04-01, Business scope includes pharmaceutical products,medical instruments,medical equipment,Green facilities,Sanitary materials and accessories,Chemical raw materials(Does not contain dangerous goods),Technology development of health food and health products,Technical Services,technology transfer,Technical consultation, maintenance and installation;General consumer goods economic information consultation;Biotechnology Information Consulting. (Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Imperial Innovations is a technology commercialization and venture capital investor that focuses on technology. Imperial Innovations no longer invests in startups and now functions as the technology-transfer office of Imperial College. Imperial Innovations is focused on commercialising leading UK academic research sourced from the 'golden triangle' formed between Cambridge, Oxford and London. We are a technology commercialisation company that combines the activities of technology transfer, intellectual property protection and licensing, company incubation and investment. Innovations is focused on commercialising the most promising UK academic research across a broad range of technology sectors, and has developed particular expertise in: therapeutics, medtech, engineering and materials and information communication technology.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Pharma Development Holding GmbH is a private company headquartered in Dusseldorf, Germany. The firm provides financial services. It was founded in 2011.

Part of Galapagos NV, ProSkelia SAS is a company headquartered in Romainville, France, that conducts bone disease research. It was founded by Roland Baron. On December 22, 2006 Galapagos Genomics NV acquired ProSkelia SAS from Kyowa Kirin International Plc for $59.24 million.

Longhua Hospital Shanghai University of TCM, a subsidiary of Shanghai University of Traditional Chinese Medicine, is a company headquartered in Shanghai, China. The firm provides hospital services.

Nihon Medi-Physics Co., Ltd. is a Japanese joint venture company located in Koto-ku focused on pharmaceutical preparations. The firm was founded in 1973. Nobuhiko Tamura is the current CEO of the company.\nThe company says this about itself: Nihon Medi-Physics is engaging in ensuring stable supply and research and development of the products as a leading manufacturer of radiopharmaceuticals in Japan. Based on the technological proficiency and trust built over the years, the company is also working on research and development of \"Theranostics (a combination of therapy and diagnosis),\" which is a novel medical technology to provide optimal medical service to each patient, as well as on the dissemination of nuclear medicine in Asian countries by licensing its products. The company will continue contributing to society by creating values as a life science company.

Roche Diagnostics GmbH, part of Roche Holding AG, is a company headquartered in Mannheim, Germany, involved in laboratory analytical instruments. Andreas Schmitz and Claus Haberda are the current co-CEOs of the firm. On January 01, 1999 Roche Holding AG acquired Roche Diagnostics GmbH.